伴SH2B3纯合胚系突变的骨髓增殖性肿瘤:一例报告及文献复习
回顾性分析国内首例由SH2B3基因纯合胚系突变驱动的骨髓增殖性肿瘤(MPN)患者的临床资料。患者为59岁女性,二代测序检出SH2B3 c.1481C>A p.S494*纯合胚系突变(VAF 100%),家系分析证实胚系来源。予芦可替尼20 mg每日2次治疗后症状缓解、脾脏缩小,疗效显著。
要点
- SH2B3纯合胚系突变可驱动MPN,表现为发热、盗汗、WBC及PLT增高、脾大。
- SH2B3失活突变减弱对JAK2/STAT通路的负调控,导致通路持续激活。
- 芦可替尼20 mg每日2次治疗可改善症状并缩小脾脏。
核心结论
- SH2B3基因纯合胚系突变可通过持续激活JAK2/STAT信号通路诱导MPN发生。
- 芦可替尼20 mg每日2次治疗该患者效果显著。
研究设计与样本
- 回顾性分析国内首例SH2B3纯合胚系突变驱动MPN患者的临床资料。
- 患者为59岁女性,因间断乏力伴发热3年加重4 d入院。
主要发现
- 二代测序检出SH2B3基因c.1481C>A p.S494*纯合胚系突变,VAF为100%。
- 家系分析证实胚系来源,其子女均为SH2B3杂合突变携带者且表型正常。
- 临床主要表现为发热、盗汗、WBC及PLT增高、脾大。
- 予芦可替尼20 mg每日2次治疗后体温恢复正常、乏力缓解、盗汗消失、脾脏减小。
关键数值与推荐
- SH2B3基因突变型为c.1481C>A p.S494*,纯合胚系,VAF 100%。
- 芦可替尼用法为20 mg每日2次。
临床怎么用
- 对疑似MPN患者可行二代测序检测SH2B3基因突变,并做家系分析明确胚系来源。
- SH2B3纯合胚系突变驱动的MPN可尝试JAK1/JAK2抑制剂芦可替尼治疗。
局限性
- 为单例病例报告及文献复习,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study retrospectively analyzed the clinical data of the first reported case in China of myeloproliferative neoplasm (MPN) driven by a homozygous germline SH2B3 mutation, aiming to deepen the understanding of this rare MPN subtype. The patient was a 59-year-old female admitted due to intermittent fatigue and fever for 3 years, which had worsened 4 days prior to admission. Next-generation sequencing revealed a homozygous germline SH2B3 gene mutation (c.1481C>A, p.S494*) with a variant allele frequency (VAF) of 100%. Family analysis confirmed its germline origin, and her children were all heterozygous carriers of the SH2B3 mutation with normal phenotypes. Based on hematological examination and bone marrow pathology, MPN was definitively diagnosed. The main clinical manifestations included fever, night sweats, elevated WBC and PLT, and splenomegaly. As a negative regulator of JAK2, inactivating mutations in the SH2B3 gene lead to weakened negative regulation of the JAK2/STAT signaling pathway by the SH2B3 protein, thereby causing continuous activation of this pathway and inducing the development of MPN. After treatment with the JAK1/JAK2 inhibitor ruxolitinib 20 mg twice daily, the patient's body temperature returned to normal, fatigue and night sweats resolved, and spleen size decreased, demonstrating significant therapeutic efficacy. 回顾性分析了国内首例由SH2B3基因纯合胚系突变驱动的骨髓增殖性肿瘤(MPN)患者的临床资料,旨在加深对该罕见MPN亚型的认识。患者为59岁女性,因间断乏力伴发热3年加重4 d入院。二代测序结果显示其存在SH2B3基因c.1481C>A p.S494*纯合胚系突变[变异等位基因突变频率(VAF)100%],并通过家系分析证实为胚系来源,其子女均为SH2B3基因杂合突变携带者,表型正常。结合血液学检查及骨髓病理,明确诊断为MPN,临床主要表现为发热、盗汗、WBC及PLT增高、脾大。SH2B3基因作为JAK2的负调控因子,其失活突变导致SH2B3蛋白对JAK2/STAT信号通路的负调控作用减弱,从而引起该信号通路的持续激活,诱导MPN的发生。予JAK1/JAK2抑制剂芦可替尼20 mg每日2次治疗后,患者体温恢复正常,乏力缓解,盗汗消失,脾脏减小,治疗效果显著。.
引用
- Zhang W, Li R, Tian J, et al. [Myeloproliferative neoplasm with a homozygous germline SH2B3 mutation: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161666. doi:10.3760/cma.j.cn121090-20251019-00472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。